Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.50 |
| ▸ | TACR3 | P29371 | 13/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | TACR2 | P21452 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892659 | 0.91 | DHODH (0.44) | TACR3DHODHTACR2 | |
| SCHEMBL4893649 | 0.91 | TACR2 (0.52) | BDKRB1TACR3TACR2KCNH2TSHR | |
| SCHEMBL4893095 | 0.82 | TACR3 (0.67) | TACR3 | |
| SCHEMBL4893103 | 0.82 | TACR3 (0.67) | TACR3 | |
| SCHEMBL5482733 | 0.82 | TACR3 (0.53) | TACR3DHODHKCNH2PLA2G2A | |
| SCHEMBL4898679 | 0.81 | TACR3 (0.68) | TACR3 | |
| SCHEMBL4898683 | 0.81 | TACR3 (0.68) | TACR3 | |
| SCHEMBL4668037 | 0.80 | TACR3 (0.53) | TACR3DHODHPLA2G2A | |
| SCHEMBL4884299 | 0.80 | DHODH (0.50) | TACR3DHODHTACR2KCNH2TSHR | |
| SCHEMBL4887323 | 0.79 | TACR3 (0.67) | TACR3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | TACR1, TACR2, KCNA3 | BDKRB1 46/4885TACR3 10/4885DHODH 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.